Clearside – $36 Million Public Offering

Reston – January 3, 2017 – Cooley advised Clearside Biomedical on its $36 million public offering of 4,000,000 shares of common stock.

Clearside, which trades on the NASDAQ Global Market under the symbol “CLSD,” is a late-stage clinical biopharmaceutical company developing innovative drug therapies to treat blinding diseases of the eye.

In addition to representing Clearside on the offering, Cooley has served as intellectual property counsel to the company since 2012. Earlier this year, Cooley also advised Clearside on its $50 million IPO.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Brian Leaf Partner, Reston
Brent Siler Partner, Washington, DC
Darren DeStefano Partner, Reston
Mark Ballantyne Associate, Reston
Katie Kazem Associate, Reston
Michael Tuscan Partner in Charge - Washington, DC
Erik Milch Partner, Reston
Jeremy Binstock Associate, Reston
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York
Mark Windfeld-Hansen Partner, Palo Alto
Keith Ranta Special Counsel, Washington, DC
Francis Wheeler Partner, Colorado